New and Emerging Therapies for the Treatment of Non-alcoholic Steatohepatitis: The Role of the Pharmacist in Early Identification and Clinical Intervention
1.5 Credits / Nephrology
Rare and Treatment-Resistant Epilepsy Syndromes: Identifying and Addressing the Unmet Needs of Patients and Recognizing Opportunities for Pharmacist Intervention
1.5 Credits / Neurology
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
Assessing the Role of Antibody-Drug Conjugates in Breast Cancer Treatment Pathways
1.0 Credit / Oncology
Opportunities to Optimize Treatment of Non-Small Cell Lung Cancer and Gastric Cancers With Antibody-Drug Conjugates
1.0 Credit / Oncology
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Disease, Respiratory, Immunization
Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer
0.5 Credit / Oncology, Women’s Health
Demystifying the Details of T-Cell Engaging Bispecific Antibodies: Establishing a Foundation for Oncology Pharmacists
2.0 Credits / Oncology
FDA Grants Fast Track Designation to Milvexian for Multiple Prospective Cardiovascular IndicationsJune 6th 2023
The proposed indications for milvexian include stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.
Obstructive Sleep Apnea May Have Significant Impact on Cognitive Decline in Middle-Aged IndividualsJune 6th 2023
Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.
Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple MyelomaJune 6th 2023
Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.
Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung CancerJune 5th 2023
In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.
Overall Survival of Patients With Metastatic NSCLC Sustained Up to 4 Years With Opdivo, Yervoy CombinationJune 5th 2023
Nivolumab plus ipilimumab combination improved overall survival, with 21% of individuals with metastatic non–small cell lung cancer treated with the combination and 2 cycles of chemotherapy alive compared to 16% with chemotherapy alone.
Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian CancerJune 5th 2023
Positive findings in patients with advanced high-grade epithelial ovarian cancer were presented during an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting.
FDA Approves First Intravenous Iron Replacement Therapy for Adults With Heart Failure, Iron DeficiencyJune 5th 2023
Treatment with Injectafer significantly improved exercise capacity compared to placebo in a randomized clinical trial in adult patients with heart failure.
Clinical Overview: Steps to Implementation of Rebyota for Recurrent C difficile InfectionJune 5th 2023
Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers with different steps in the eventual administration process.
Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLCJune 5th 2023
Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.
With Perioperative Pembrolizumab, Event-Free Survival for Early-Stage Lung Cancer Was 62% at the Interim Analysis of Phase 3 KEYNOTE-671June 4th 2023
Expert said these striking results, coupled with benefits across all subgroups and potential overall survival, suggests efficacy for adults with early-stage non-small cell lung cancer.
Addition of Pembrolizumab to Chemotherapy Can Significantly Improve Survival Outcomes in Patients with Cervical CancerJune 4th 2023
Expert discusses the long wait for an effective therapeutic option for persistent, recurrent, or metastatic cervical cancer and the potential widespread benefits of antibody drug conjugates like pembrolizumab.
New Manufacturing Process Could Improve CAR T Cell Efficacy Against Aggressive Form of LeukemiaJune 3rd 2023
Expert said that manufacturing the T cells with a tyrosine kinase inhibitor may allow more patients to get allogeneic stem cell transplant, the current best means of long-term cure.